Invesco Biotechnology & Genome ETF (PBE) Short Interest Ratio & Short Volume

Short interest is the volume of Invesco Biotechnology & Genome ETF shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 1,400 shares of PBE short. 0.04% of Invesco Biotechnology & Genome ETF's shares are currently sold short. Learn More on Invesco Biotechnology & Genome ETF's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.04% of Invesco Biotechnology & Genome ETF's floating shares are currently sold short.

Invesco Biotechnology & Genome ETF saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,400 shares, an increase of 180.0% from the previous total of 500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.04% of Invesco Biotechnology & Genome ETF's shares are currently sold short. Here is how the short interest of companies compare to Invesco Biotechnology & Genome ETF: Invesco Pharmaceuticals ETF (0.19%), SPDR S&P Health Care Equipment ETF (441.46%), SPDR S&P Pharmaceuticals ETF (4.83%), Simplify Health Care ETF (0.40%), Direxion Daily Healthcare Bull 3x Shares (4.19%), VanEck Biotech ETF (0.18%), KraneShares MSCI All China Health Care Index ETF (1.12%), Invesco Dorsey Wright Healthcare Momentum ETF (0.25%), SPDR S&P Health Care Services ETF (4.34%), ALPS Medical Breakthroughs ETF (0.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling PBE is an investing strategy that aims to generate trading profit from Invesco Biotechnology & Genome ETF as its price is falling. PBE shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Invesco Biotechnology & Genome ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PBE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PBE, twice per month. The most recent reporting period available is June, 30 2025.